Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Popula...(equired colonoscopy alone andthose with ...),Health

Date:5/20/2008

equired colonoscopy alone, and those with treatable Stage II (Dukes Stage B) cancer (n=2) were diagnosed an average of 21.8 months earlier than they would have been with a study-required colonoscopy alone. Detection of advanced adenomas in the FIT cohort (n=60; non-FIT n=54) occurred 18.4 months earlier than would have occurred during the study-required colonoscopy.

Overall, the interim report showed that interval FIT testing under this study program detected 86 percent (12 of 14) of colorectal cancers and 63 percent (60 of 96) of advanced adenomas greater than 10 mm.

Colorectal cancer is the second leading cause of cancer death in the United States(1), but when found early and treated, the five-year relative survival rate for colon cancer is 90 percent.(2) Currently, less than 40 percent of colorectal cancers are found early.(3) The new data presented today at DDW suggest that annual colorectal screening with FIT tests may help increase early detection.

"Our interim report indicates that undertaking annual FIT testing in high-risk groups -- between planned surveillance colonoscopies -- is valuable because it reduces delays in the diagnosis and treatment of colorectal cancer and advanced adenomas," said primary investigator Graeme P. Young, MD, FRACP, Professor of Gastroenterology and Academic Head of GI Services, Director, Flinders Centre for Innovation in Cancer of South Australia. "For the medical community dedicated to preventing and treating this major disease, we now have evidence that annual screening of high-risk patients with a convenient, take-at-home test can catch not only colorectal cancer earlier but advanced adenomas as well, given the notable CSP study program sensitivity of 63 percent."

American Cancer Society (ACS) guidelines recommend colonoscopy every five years for patients with a family history of colorectal cancer and for patients with a personal history of colorectal cancer who have had a normal 3-year colonoscopy,
'/>"/>

SOURCE Quest Diagnostics Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
2. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
4. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
7. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
10. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting